Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients

被引：40
作者：
Sai, Kimie [1 ]
Saito, Yoshiro [2 ]
Sakamoto, Hiromi [3 ]
Shirao, Kuniaki [4 ]
Kurose, Koichi [5 ]
Saeki, Mayumi [6 ]
Ozawa, Shogo [7 ]
Kaniwa, Nahoko [5 ]
Hirohashi, Setsuo [8 ]
Saijo, Nagahiro [9 ]
Sawada, Jun-ichi [2 ]
Yoshida, Teruhiko [3 ]
机构：
[1] Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, Tokyo 1588501, Japan
[2] Natl Inst Hlth Sci, Dept Biochem & Immunochem, Setagaya Ku, Tokyo 1588501, Japan
[3] Natl Inst Canc Res, Div Genet, Chuo Ku, Tokyo 1040045, Japan
[4] Natl Canc Ctr, Div Internal Med, Chuo Ku, Tokyo 1040045, Japan
[5] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, Tokyo 1588501, Japan
[6] Natl Inst Hlth Sci, Project Team Pharmacogenet, Setagaya Ku, Tokyo 1588501, Japan
[7] Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan
[8] Natl Inst Canc Res, Div Pathol, Chuo Ku, Tokyo 1040045, Japan
[9] Natl Canc Ctr Hosp E, Chiba 2778577, Japan
来源：
CANCER LETTERS | 2008年 / 261卷 / 02期
关键词：
UGT1A1; pharmacogenetics; irinotecan; SN-38;
D O I：
10.1016/j.canlet.2007.11.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent pharmacogenetic studies on irinotecan have revealed the impact of UDP glucuronosyltransferase (UGT) 1A1*28 on severe irinotecan toxicities. Although the clinical role of UGT1A1*6, which is specifically detected in East Asian patients, in irinotecan toxicities is suggested, clear evidence remains limited. To examine the impact of *6, the association of UGT1A1 genotypes with severe irinotecan toxicities was retrospectively investigated in Japanese cancer patients. A significant *6-dependent increase in the incidence of grade 3 or 4 neutropenia was observed in 49 patients on irinotecan mono-therapy (p = 0.012). This study further clarifies the clinical importance of *6 in irinotecan therapy in East Asians. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：165 / 171
页数：7
相关论文
共 23 条
  • [1] Ando Y, 2000, CANCER RES, V60, P6921
  • [2] Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer
    Araki, Kazuhiro
    Fujita, Ken-Ichi
    Ando, Yuichi
    Nagashima, Fumio
    Yamamoto, Wataru
    Endo, Hisashi
    Miya, Toshimichi
    Kodama, Keiji
    Narabayashi, Masaru
    Sasaki, Yasutsuna
    [J]. CANCER SCIENCE, 2006, 97 (11): : 1255 - 1259
  • [3] Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
    Ciotti, M
    Basu, N
    Brangi, M
    Owens, IS
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 260 (01) : 199 - 202
  • [4] DEFORNI M, 1994, CANCER RES, V54, P4347
  • [5] Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)
    Gagné, JF
    Montminy, V
    Belanger, P
    Journault, K
    Gaucher, G
    Guillemette, C
    [J]. MOLECULAR PHARMACOLOGY, 2002, 62 (03) : 608 - 617
  • [6] GUPTA E, 1994, CANCER RES, V54, P3723
  • [7] Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
    Han, Ji-Youn
    Lim, Hyeong-Seok
    Shin, Eun Soon
    Yoo, Yeon-Kyeong
    Park, Yong Hoon
    Lee, Jong-Eun
    Jang, In-Jin
    Lee, Doe Ho
    Lee, Jin Soo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2237 - 2244
  • [8] Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin
    Hanioka, N
    Ozawa, S
    Jinno, H
    Ando, M
    Saito, Y
    Sawada, J
    [J]. XENOBIOTICA, 2001, 31 (10) : 687 - 699
  • [9] Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    Innocenti, F
    Undevia, SD
    Iyer, L
    Chen, PX
    Das, S
    Kocherginsky, M
    Karrison, T
    Janisch, L
    Ramírez, J
    Rudin, CM
    Vokes, EE
    Ratain, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1382 - 1388
  • [10] UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    Iyer L.
    Das S.
    Janisch L.
    Wen M.
    Ramírez J.
    Karrison T.
    Fleming G.F.
    Vokes E.E.
    Schilsky R.L.
    Ratain M.J.
    [J]. The Pharmacogenomics Journal, 2002, 2 (1) : 43 - 47
123